featured
Inebilizumab Reduces Risk of Attacks in NMOSD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Multiple Sclerosis (Houndmills, Basingstoke, England)
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sensitivity Analysis of the Primary Endpoint From the N-MOmentum Study of Inebilizumab in NMOSD
Mult. Scler. 2021 Feb 04;[EPub Ahead of Print], BA Cree, JL Bennett, HJ Kim, BG Weinshenker, SJ Pittock, D Wingerchuk, K Fujihara, F Paul, GR Cutter, R Marignier, AJ Green, O Aktas, HP Hartung, IM Williams, J Drappa, D She, D Cimbora, W Rees, JN Ratchford, E KatzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.